Download MendeleyA novel class of oral direct Renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
Ostermann, N., Ruedisser, S., Ehrhardt, C., Breitenstein, W., Marzinzik, A., Jacoby, E., Vangrevelinghe, E., Ottl, J., Klumpp, M., Hartwieg, J.C., Cumin, F., Hassiepen, U., Trappe, J., Sedrani, R., Geisse, S., Gerhartz, B., Richert, P., Francotte, E., Wagner, T., Kromer, M., Kosaka, T., Webb, R.L., Rigel, D.F., Maibaum, J., Baeschlin, D.K.(2013) J Med Chem 56: 2196-2206
- PubMed: 23360239
- DOI: https://doi.org/10.1021/jm301706j
- Primary Citation of Related Structures:
4GJ8, 4GJ9, 4GJA, 4GJB, 4GJC, 4GJD - PubMed Abstract:
A small library of fragments comprising putative recognition motifs for the catalytic dyad of aspartic proteases was generated by in silico similarity searches within the corporate compound deck based on rh-renin active site docking and scoring filters. Subsequent screening by NMR identified the low-affinity hits 3 and 4 as competitive active site binders, which could be shown by X-ray crystallography to bind to the hydrophobic S3-S1 pocket of rh-renin. As part of a parallel multiple hit-finding approach, the 3,5-disubstituted piperidine (rac)-5 was discovered by HTS using a enzymatic assay. X-ray crystallography demonstrated the eutomer (3S,5R)-5 to be a peptidomimetic inhibitor binding to a nonsubstrate topography of the rh-renin prime site. The design of the potent and selective (3S,5R)-12 bearing a P3(sp)-tethered tricyclic P3-P1 pharmacophore derived from 3 is described. (3S,5R)-12 showed oral bioavailability in rats and demonstrated blood pressure lowering activity in the double-transgenic rat model.
Organizational Affiliation:
Novartis Pharma AG, Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland.
